Vivos Therapeutics Raises $2.1M in PIPE, Securing Critical Liquidity
VVOS sits 25% above its 52-week low of $0.383 on light trading volume (0.1× avg).
Summary
Vivos Therapeutics completed a $2.1 million private placement (PIPE) with V-Co Investors 4 and Bigger Capital Fund, comprising $1.0 million in new cash and the conversion of a $1.0 million bridge note. This financing follows recent reports of significant net losses, a 'going concern' warning, and a Nasdaq non-compliance notice regarding stockholders' equity. The company also recently restructured $4.5 million in senior debt into equity. This capital infusion provides critical, albeit short-term, liquidity for a company facing severe financial challenges and delisting risk. The company's ability to achieve profitability and maintain Nasdaq compliance will be crucial going forward.
At the time of this announcement, VVOS was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.38 to $7.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.